Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants

AIDS

Volumn 28, Issue 3, 2014, Pages 335-344

  Palella Jr , Frank J ^a   Fisher, Martin ^b   Tebas, Pablo ^c   Gazzard, Brian ^d   Ruane, Peter ^e   Van Lunzen, Jan ^f   Shamblaw, David ^g   Flamm, Jason ^h   Ebrahimi, Ramin ⁱ   Porter, Danielle ⁱ   White, Kirsten ⁱ   Hindman, Jason ⁱ   Elbert, Elizabeth ⁱ   De Oertel, Shampa ⁱ   Fralich, Todd ⁱ  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Worthing Hospital   (United Kingdom)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^e James R Berenson MD Inc   (United States)

^f UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^g La Playa Medical Group and Clinical Research   (United States)

^h KAISER PERMANENTE   (United States)

ⁱ GILEAD SCIENCES   (United States)

Author keywords

Boosted protease inhibitor; HIV 1; Rilpivirine; Single tablet regimen; Switch study; Tenofovir; Treatment simplification

Indexed keywords

ADULT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84894107031     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000087     Document Type: Article

References (21)

1. US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 12 February 2013. http://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv- guidelines/0/. [Accessed 19 February 2013].
2. European AIDS Clinical Society. EACS Guidelines Version 6.1 - November 2012. http://www.europeanaidsclinicalsociety.org/images/stories/EACS-Pdf/ EacsGuidelines-v6.1-2edition.pdf. [Accessed 19 February 2013].
3. Thompson MA, Mugavero MJ, Amico KR, Cargill VA, Chang LW, Gross R, et al. Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care panel. Ann Intern Med 2012; 156:817-833.
4. Thompson MA, Aberg JA, Hoy JF, Telenti A, Benson C, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA Panel. JAMA 2012; 308:387-402.
5. Nachega JB, Mugavero MJ, Zeier M, Vitó ria M, Gallant JE. Treatment simplification in HIV-infected adults as a strategy to prevent toxicity, improve adherence, quality of life and decrease healthcare costs. Patient Prefer Adherence 2011; 5:357-367.
6. DeJesus E, Pozniak A, Gallant J, Arribas J, Zhou Y, Warren D, Enejosa J. Improvement in fasting lipids but minimal recovery of limb fat were seen 96 weeks after switching from lamivudine/zidovudine plus efavirenz to fixed-dose efavirenz/emtricitabine/tenofovir DF in HIV-infected patients [abstract H-1572]. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 12-15 September 2009, San Francisco, CA USA.
7. Airoldi M, Zaccarelli M, Bisi L, Bini T, Antinori A, Mussini C, et al. One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects. Patient Prefer Adherence 2010; 4:115-125.
8. Bangsberg DR, Ragland K, Monk A, Deeks SG. A single tablet regimen is associated with higher adherence and viral suppression than multiple tablet regimens in HIVR homeless and marginally housed people. AIDS 2010; 24:2835-2840.
9. Cohen CJ, Molina JM, Cassetti I, Chetchotisakd P, Lazzarin A, Orkin C, et al. Week 96 efficacy and safety of rilpivirine in treatment-naïve, HIV-1 patients in two phase III randomized trials. AIDS 2013; 27:939-950.
10. Cohen CJ, Andrade-Villanueva J, Clotet B, Fourie J, Johnson MA, Ruxrungtham K, et al., for the THRIVE study group. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, noninferiority trial. Lancet 2011; 378:229-237.
11. Molina J-M, Cahn P, Grinsztejn B, Lazzarin A, Mills A, Saag M, et al., for the ECHO study group. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet 2011; 378:238-246.
12. Smith F, Hammerstrom T, Soon G, Zhou S, Chen B, Mai Y, et al. Ameta-analysis to assess the FDADAVP's TLOVR algorithm in HIV submissions. Drug Information J 2011; 45:291-300.
13. US Department of Health and Human Services. Guidance for industry. Antiretroviral drugs using plasma HIV RNA measurements - clinical considerations for accelerated and traditional approval. October 2002. http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070968.pdf [Accessed 4 March 2013].
14. Rimsky L, Van Eygen V, Vingerhoet J, Thys K, Aerssens J, Stevens M, Picchio G. Similar prevalence of baseline HIV-1 minority variants among responders and virologic failures, as well as increased detection of HIV-1 minority variants at treatment failure, in rilpivirine patients from the ECHO and THRIVE phase III studies [abstract TUAB0302]. In: Program and Abstracts of the XX International AIDS Conference; 22-27 July 2012; Washington, DC, USA.
15. Eron JJ, Young B, Cooper DA, Youle M, Dejesus E, Andrade-Villanueva J, et al., for the SWITCHMRK 1 and 2 investigators. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet 2010; 375:396-407.
16. Mills A, Cohen C, DeJesus E, Brinson C, Yale K, Ramanathan S, et al. Virologic suppression is maintained in virologically suppressed HIV-1 infected subjects switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) single-tablet regimen (STR) to emtricitabine/rilpivirine/tenofovir disoproxil fumarate (FTC/RPV/TDF) STR: week 24 results of study 264-111 [abstract P186]. In: Program and abstracts of the 18th Annual Conference of the British HIV Association; 18-20 April 2012, Birmingham, UK.
17. Data Collection on Adverse Events of Anti-HIV Drugs Study Group. Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction. Clin Infect Dis 2008; 46:1101-1110.
18. Palella FJ Jr, Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT, et al., for the HIV Outpatient Study Investigators. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006; 43: 27-34.
19. US Department of Health and Human Services. Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). May 2001. http://www.nhlbi.nih.gov/guidelines/cholesterol/atp3full.pdf. [Accessed 5 March 2013].
20. Dube MP, Stein JH, Aberg JA, Fichtenbaum CJ, Gerber JG, Tashima KT, et al., for the Adult AIDS Clinical Trials Group Cardiovascular Subcommittee. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 2003; 37:613-627.
21. Lundgren JD, Battegay M, Behrens G, De Wit S, Guaraldi G, Katlama C, et al., for the European AIDS Clinical Society Executive Committee. European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV. HIV Med 2008; 9:72-81.